Applegate’s experience underscores the challenge of diagnosing MS early while avoiding mistakes, as imaging and biomarkers help clinicians identify it sooner.
Earlier diagnosis, greater consequences
Diagnosing multiple sclerosis early can give treatment more time to limit lasting neurological damage. But the push to act sooner carries a cost: clinicians must distinguish MS from other conditions before a pattern of symptoms has fully emerged. Actor Christina Applegate’s recent disclosure illustrates that tension. Five years after receiving an MS diagnosis, she said she’d been misdiagnosed.
That account doesn’t explain what led to her diagnosis or what doctors later concluded, so it can’t serve as a guide to her individual care. It does, however, point to a broader problem in neurology: symptoms that raise concern for MS can be difficult to interpret, especially early on. A diagnosis can shape treatment decisions and a patient’s understanding of their health for years. Getting it wrong can carry real consequences.
Why MS can be difficult to identify
Multiple sclerosis affects the central nervous system, which includes the brain and spinal cord. The disease can damage myelin, the protective covering around nerve fibers, disrupting signals that travel through the nervous system. Its effects vary from person to person, and symptoms may involve different parts of the body. That variability makes a single symptom an unreliable basis for diagnosis.
Neurologists have to consider whether a patient’s symptoms fit MS and whether other explanations might fit better. A symptom can be real and disabling without identifying its cause. The challenge is to connect a person’s clinical history with findings from examination and tests, then judge whether the pieces support MS strongly enough to make the diagnosis.
There’s a difficult balance here. Waiting for more evidence may delay treatment, while moving too quickly can attach a serious diagnosis to symptoms that have another explanation. This is more significant than it looks: the name of a disease can influence which treatments a person receives and how future symptoms are understood.
What has changed in diagnosis
When the author of the source began practicing nearly 40 years ago, physicians often needed symptoms to recur before they could confirm MS. That approach reflected the limits of the evidence available at the time: clinicians needed to see a pattern develop. Today, imaging, biomarkers and updated diagnostic criteria give them more ways to assess the disease earlier.
These tools help doctors evaluate evidence that may not be visible from symptoms alone. Imaging can show changes in the brain or spinal cord, while biomarkers can add information about disease processes. Diagnostic criteria help clinicians interpret those findings alongside a patient’s history and examination. No single test should be read in isolation; the diagnosis depends on how the evidence fits together.
Earlier identification can give treatment more time to reduce the risk of lasting neurological harm, as the source describes. But earlier also means that clinicians may have less time to observe how symptoms develop. Better tools have changed what doctors can see; they haven’t removed the need for careful judgment.
The limits of tests and criteria
Imaging and biomarkers can strengthen a case for MS, but their value depends on context. A scan is a piece of evidence, not a complete account of why someone has symptoms. Clinicians still need to ask whether test results match the patient’s experience and whether another condition could explain them. Criteria can make decisions more consistent, but they don’t replace that clinical work.
(And this is the part most people overlook.) A diagnosis is not simply a label produced by a test. It’s an interpretation made from findings that may change as more information becomes available. When later evidence conflicts with an earlier conclusion, doctors may need to reassess what they thought they knew.
That process can be unsettling for patients. A misdiagnosis can mean that a person has spent years understanding their health through the wrong explanation. At the same time, the possibility of an error doesn’t establish that any particular diagnosis was careless or that any one test failed. The source provides no details about Applegate’s case beyond her disclosure.
Implications for patients and clinicians
For clinicians, the challenge is to make a timely decision while keeping uncertainty visible. That means weighing symptoms, examination findings, imaging, biomarkers and diagnostic criteria together, and revisiting the conclusion if the evidence changes. Good diagnostic tools can support that judgment; they can’t make every difficult case straightforward.
If you’re working in this space, the central question is how to use earlier evidence without treating speed as proof of accuracy. Patients, meanwhile, may want to understand what findings support a diagnosis and how doctors would respond if new information points elsewhere. Those questions are especially relevant when symptoms are changing or the available evidence remains incomplete.
The broader lesson is plain. Neurology can identify MS earlier than it once could, and earlier treatment may help limit lasting damage. Yet the same pressure to intervene promptly makes diagnostic precision essential. More evidence can narrow uncertainty. It can’t always erase it.
Discussion
Sign in to join the discussion.